Context-dependent functionality of 2'-fucosyllactose with Bifidobacterium breve M-16 V and short-chain galacto-/long-chain fructo-oligosaccharides in infant gut fermentation.
Guo W, Zhou B, et al. • Food research international (Ottawa, Ont.) • 2026
The functional expression of 2'-FL was broadened in an scGOS/lcFOS-supported microbial context containing B. breve M-16V, with the combined GFFB treatment showing the strongest bifidogenic, metabolic, and anti-inflammatory effects.
Key Findings
Results
2'-FL alone showed limited bifidogenic activity and weak support for microbial growth in the infant gut fermentation model.
A continuous in vitro fermentation system was inoculated with fecal microbiota from four donors selected from 22 infant volunteers.
Five treatments were compared: 2'-FL alone, GF (scGOS/lcFOS), GFB (GF + B. breve M-16V), GFF (GF + 2'-FL), and GFFB (GF + 2'-FL + B. breve M-16V).
The limitation of 2'-FL applied alone was attributed to insufficient 2'-FL-utilizing bacteria in the microbiota.
The study used a day-10 stabilization baseline for comparison of treatment effects.
Results
The GFFB combination (scGOS/lcFOS + 2'-FL + B. breve M-16V) substantially increased Bifidobacterium relative abundance compared to baseline.
GFFB increased Bifidobacterium to 205.62% of the day-10 stabilization baseline (P < 0.01).
This bifidogenic effect was greater than that observed with 2'-FL alone or GF alone.
The combination of scGOS/lcFOS provided a substrate-supported microbial context that enabled 2'-FL's functional expression.
B. breve M-16V was identified as a key component enabling 2'-FL utilization in this system.
GFFB reduced Pseudomonadota to 14% of the day-10 stabilization baseline (P < 0.001).
This reduction was notably stronger than reductions observed in other treatment groups.
Reduction of Pseudomonadota is considered beneficial in the context of infant gut health.
Results
GFFB treatment increased short-chain fatty acid production, specifically acetate and propionate, compared to other treatments.
GFFB increased acetate to 140% of the 2'-FL alone group (P < 0.01).
GFFB increased propionate to 110% of the day-10 stabilization baseline (P < 0.05).
GFFB also enriched tryptophan-derived indoles in the fermentation system.
These metabolic outputs were evaluated as indicators of the functional performance of the combined treatment.
Results
Cell-free fermentation supernatants from GFFB showed the strongest attenuation of LPS-induced inflammatory responses in RAW 264.7 macrophages.
Immunomodulatory activity was evaluated using cell-free fermentation supernatants rather than direct ingredient exposure.
GFFB-derived supernatants reduced IL-1β to 26.70% of the LPS control (P < 0.001).
GFFB-derived supernatants reduced IL-6 to 57.50%, nitric oxide to 29.84%, and TNF-α to 35.91% of the LPS control (all P < 0.001).
This anti-inflammatory evaluation methodology tested the effect of microbial metabolic products rather than the prebiotic/probiotic ingredients themselves.
Discussion
The functional performance of 2'-FL was context-dependent, requiring an scGOS/lcFOS-supported microbial environment with B. breve M-16V for full expression.
2'-FL's efficacy was limited when applied alone due to insufficient 2'-FL-utilizing bacteria in the microbiota.
The GFFB combination outperformed all other treatment groups (2'-FL, GF, GFB, GFF) across bifidogenic, metabolic, and immunomodulatory outcomes.
The study concluded that the functional expression of 2'-FL was broadened in an scGOS/lcFOS-supported microbial context containing B. breve M-16V.
Four infant fecal donors were selected from 22 infant volunteers to represent the target microbiota context.
What This Means
This research suggests that a human milk sugar called 2'-fucosyllactose (2'-FL), which is found naturally in breast milk and added to some infant formulas, does not work as well on its own as it does when combined with other prebiotics and a specific probiotic bacterium. In a laboratory gut fermentation model using infant stool samples, 2'-FL alone showed limited ability to promote the growth of beneficial Bifidobacterium bacteria. However, when 2'-FL was combined with a prebiotic fiber mixture (scGOS/lcFOS) and the probiotic Bifidobacterium breve M-16V, the combination dramatically increased beneficial bacteria (to over twice the baseline level), reduced potentially harmful bacteria to just 14% of baseline, and boosted the production of beneficial metabolites including short-chain fatty acids and tryptophan-derived compounds.
The study also found that the liquid produced by the gut bacteria during fermentation with the full combination (2'-FL + prebiotic fibers + B. breve M-16V) had the strongest ability to reduce inflammation in immune cells in the laboratory, cutting levels of inflammatory molecules like IL-1β, TNF-α, and nitric oxide to as low as 26-36% of inflamed control levels. This suggests the anti-inflammatory benefit came from what the gut bacteria produced, not the ingredients themselves.
This research suggests that the health benefits of 2'-FL are highly dependent on the surrounding microbial environment — meaning that without the right bacteria already present to use 2'-FL, its benefits may be limited. Combining 2'-FL with complementary prebiotic fibers and specific probiotic bacteria that can utilize it may be a more effective strategy for supporting infant gut health and immune development than using 2'-FL alone.
Check Your Own Numbers
Upload your bloodwork. We'll cross-reference your results against this study and 4,700 others.
Guo W, Zhou B, An Y, Qiu H, Zhang L, Zhao X, et al.. (2026). Context-dependent functionality of 2'-fucosyllactose with Bifidobacterium breve M-16 V and short-chain galacto-/long-chain fructo-oligosaccharides in infant gut fermentation.. Food research international (Ottawa, Ont.). https://doi.org/10.1016/j.foodres.2026.120387